Simon Jupp

Simon is a senior counsel and all-round brands lawyer advising on trade mark litigation, portfolio strategy and advertising.

Simon supports clients on the full range of contentious and non-contentious soft IP matters including litigation, commercial transactions, anti-counterfeiting, domain names and trade mark portfolio management. This dovetails with his work in advertising, advising clients on their appointments of creative and media agencies, with copy clearance, regulatory compliance, investigations, complaints and disputes, sponsorship and influencer agreements, and all advertising and consumer rights issues.

Simon's dual IP and advertising expertise enables him to provide a holistic approach to protecting and enhancing brands. Simon sits on the Anti-Counterfeiting Committee of ECTA, the European trade marks association.

Green Advertising

Umweltschutz und Nachhaltigkeit in Unternehmenskommunikation und Werbung

Alle relevanten und aktuellen Informationen auf einen Blick!

CV

Since 2023 Senior Counsel, Taylor Wessing

2020 - 2023 Senior Associate, Taylor Wessing

2017 - 2020 Associate, Taylor Wessing

Karriere

Since 2023 Senior Counsel, Taylor Wessing

2020 - 2023 Senior Associate, Taylor Wessing

2017 - 2020 Associate, Taylor Wessing

Ausbildung

2015 Admitted as a lawyer, England & Wales

2013 Legal Practice Course, BBP Law School London

2012 Graduate Diploma in Law, BBP Law School London

Publikationen

Featured commenting on research from the Uni of Exeter on whether copyright can be applied to the walks of catwalk models in The Times
Quoted on the topic of copyright in white noise, World Intellectual Property Review, 2018
Quoted discussing the implications of blockchain technology for IP, The Times, 2018
Has time run out for the Anne Frank Fonds?, Intellectual Property Magazine, February 2016
Google and the right to be forgotten, Lawcareers.net, February 2015

Mitgliedschaften

IPSoc

AIPPI

Fremdsprachen

Awards

Managing Intellectual Property IP Stars

Featured

Legal 500 UK 2020

Legal 500 UK 2019

Managing Intellectual Property - IP Stars 2019

Experience

Glenmark Pharma on the sale of its portfolio of CNS products in Poland to Neuraxpharm

Advised Glenmark Pharma on its divestment of its CNS business in Poland including its portfolio of generics and branded generics products and the transfer of its commercial team in Poland to private equity backed Neuraxpharm, a specialty pharmaceutical company focused on the treatment of CNS disorders.

Press release

Colin McCall

Emma Danks

Simon Jupp

Jason Rawkins

Graham Samuel-Gibbon

Apotex's EUR74m sale of subsidiaries to Aurobindo

Apotex on the sale of six European subsidiaries in Belgium, Poland, the Netherlands, Czech Republic and Spain, to Aurobindo for EUR74 million. This highly complex transaction involved the share transfer of subsidiaries in multiple jurisdictions being co-ordinated and managed by our UK team. We simultaneously advised on a multitude of business separation, ongoing product supply agreements and IP licences for the European business to continue operating after being removed from the Apotex group.

Colin McCall

Simon Cohen

Tasmina Goraya, PhD

Jason Rawkins

Simon Jupp

Bart Hunnekens

Roos Seesing